Trials / Completed
CompletedNCT03670342
Pilot Study of Somatostatin Receptor Imaging in Nasopharyngeal Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 20 (actual)
- Sponsor
- National Cancer Centre, Singapore · Academic / Other
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
Hypothesis: To estimate the proportion of locally advanced, recurrent or metastatic nasopharyngeal cancer patients which show high somatostatin receptor density (SUVmax \>10) on Ga-68 DOTATATE imaging. Galium-68 DOTATATE: PET imaging will be performed with a PET/CT scanner. Galium-68 DOTATATE will be injected intravenously. Scanning will be performed approximately 60 minutes after the injection. The standardized uptake value (SUV) will be used in the interpretation of the Ga-68 DOTATATE scans. The values gathered will be used as an estimate of the somatostatin receptor density. A patient will be considered to have an overall high somatostatin receptor density if the average SUVmax of all the representative lesions is more than 10.
Conditions
Timeline
- Start date
- 2015-08-20
- Primary completion
- 2019-04-15
- Completion
- 2019-04-15
- First posted
- 2018-09-13
- Last updated
- 2020-04-30
Locations
1 site across 1 country: Singapore
Source: ClinicalTrials.gov record NCT03670342. Inclusion in this directory is not an endorsement.